Elutia, Inc. - Class A Common Stock (ELUT)
1.0100
+0.00 (0.00%)
NASDAQ · Last Trade: May 5th, 6:08 AM EDT
Detailed Quote
| Previous Close | 1.010 |
|---|---|
| Open | - |
| Bid | 0.8800 |
| Ask | 1.100 |
| Day's Range | N/A - N/A |
| 52 Week Range | 0.5000 - 2.640 |
| Volume | 0 |
| Market Cap | 654.76K |
| PE Ratio (TTM) | -1.161 |
| EPS (TTM) | -0.9 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 59,523 |
Chart
About Elutia, Inc. - Class A Common Stock (ELUT)
Elutia, Inc. is a biotechnology company focused on developing and commercializing innovative therapies that aim to address unmet medical needs. The company specializes in regenerative medicine, particularly in the areas of tissue engineering and cell therapy, working to create advanced solutions that enhance the body's natural healing processes. Through rigorous research and development, Elutia is dedicated to transforming the treatment landscape for various conditions, improving patient outcomes, and contributing to the advancement of healthcare technologies. Read More
News & Press Releases
MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.
By TELA Bio, Inc. · Via GlobeNewswire · April 30, 2026

Elutia (ELUT) Q4 2025 Earnings Call Transcript
Via The Motley Fool · March 11, 2026
Elutia Inc (NASDAQ:ELUT) Reports Q4 Revenue Miss Amid Key FDA Submission for NXT-41chartmill.com
Via Chartmill · March 11, 2026
Wondering what's happening in Friday's pre-market session? Find an overview in this article.
Via Chartmill · October 3, 2025

Company Announces Q3 Earnings and Conference Call Dates
Via ACCESSWIRE · October 17, 2024
Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's market cap stands at $2.2 million.
Via Benzinga · September 29, 2025
Via Benzinga · September 9, 2025
Via Benzinga · August 14, 2025
Via Benzinga · April 15, 2025

ELUT stock results show that Elutia missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 7, 2024

DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies.
Via ACCESSWIRE · July 17, 2024

Although growth stocks under $5 are inherently risky and unpredictable, their very nature also facilitates robust upside potential.
Via InvestorPlace · July 11, 2024

Via Benzinga · June 17, 2024

ELUT stock results show that Elutia missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024

ELUT stock results show that Elutia missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 7, 2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via Benzinga · March 7, 2024

